Ida Robertsen

• Kvitne, Kine Eide; Hovd, Markus; Johnsen, Line Kristin; Wegler, Christine; Karlsson, Cecilia & Artursson, Per [Show all 14 contributors for this article] (2023). Digoxin Pharmacokinetics in Patients with Obesity Before and After a Gastric Bypass or a Strict Diet Compared with Normal Weight Individuals. Clinical Pharmacokinetics. ISSN 0312-5963. doi: 10.1007/s40262-023-01320-9. Full text in Research Archive
• Kvitne, Kine Eide; Drevland, Ole Martin; Haugli, Nora; Skadberg, Eline Supannee Setu; Zare, Hasse Khiabani & Åsberg, Anders [Show all 7 contributors for this article] (2023). Intraindividual Variability in Absolute Bioavailability and Clearance of Midazolam in Healthy Individuals. Clinical Pharmacokinetics. ISSN 0312-5963. 62(7), p. 981–987. doi: 10.1007/s40262-023-01257-z. Full text in Research Archive
• Drevland, Ole Martin; Robertsen, Ida; Gustavsen, Marte Theie; Kveim, Hanne Kamilla; Hovd, Markus Herberg & Midtvedt, Karsten [Show all 7 contributors for this article] (2023). Impact of Fasting Status and Circadian Variation on the Pharmacokinetics of Mycophenolate Mofetil and the Glucuronide Metabolite in Renal Transplant Recipients. Transplantation direct. ISSN 2373-8731. 9(3). doi: 10.1097/TXD.0000000000001448. Full text in Research Archive
• Hovd, Markus Herberg; Robertsen, Ida; Woillard, Jean-Baptiste & Åsberg, Anders (2023). A Method for Evaluating Robustness of Limited Sampling Strategies—Exemplified by Serum Iohexol Clearance for Determination of Measured Glomerular Filtration Rate. Pharmaceutics. ISSN 1999-4923. 15(4). doi: 10.3390/pharmaceutics15041073. Full text in Research Archive
• Hovd, Markus Herberg; Robertsen, Ida; Johnson, Line Kristin; Krogstad, Veronica; Wegler, Christine & Kvitne, Kine Eide [Show all 16 contributors for this article] (2023). Neither Gastric Bypass Surgery Nor Diet-Induced Weight-Loss Affect OATP1B1 Activity as Measured by Rosuvastatin Oral Clearance. Clinical Pharmacokinetics. ISSN 0312-5963. 62(5), p. 725–735. doi: 10.1007/s40262-023-01235-5. Full text in Research Archive
• Kvitne, Kine Eide; Åsberg, Anders; Johnson, Line Kristin; Wegler, Christine; Hertel, Jens Kristoffer & Artursson, Per [Show all 14 contributors for this article] (2022). Impact of type 2 diabetes on in vivo activities and protein expressions of cytochrome P450 in patients with obesity. Clinical and Translational Science (CTS). ISSN 1752-8054. 15(11), p. 2685–2696. doi: 10.1111/cts.13394. Full text in Research Archive Show summary

  Previous studies have not accounted for the close link between type 2 diabetes mellitus (T2DM) and obesity when investigating the impact of T2DM on cytochrome P450 (CYP) activities. The aim was to investigate the effect of T2DM on in vivo activities and protein expressions of CYP2C19, CYP3A, CYP1A2, and CYP2C9 in patients with obesity. A total of 99 patients from the COCKTAIL study (NCT02386917) were included in this cross-sectional analysis; 29 with T2DM and obesity (T2DM-obesity), 53 with obesity without T2DM (obesity), and 17 controls without T2DM and obesity (controls). CYP activities were assessed after the administration of a cocktail of probe drugs including omeprazole (CYP2C19), midazolam (CYP3A), caffeine (CYP1A2), and losartan (CYP2C9). Jejunal and liver biopsies were also obtained to determine protein concentrations of the respective CYPs. CYP2C19 activity and jejunal CYP2C19 concentration were 63% (−0.39 [95% CI: −0.82, −0.09]) and 40% (−0.09 fmol/μg protein [95% CI: −0.18, −0.003]) lower in T2DM-obesity compared with the obesity group, respectively. By contrast, there were no differences in the in vivo activities and protein concentrations of CYP3A, CYP1A2, and CYP2C9. Multivariable regression analyses also indicated that T2DM was associated with interindividual variability in CYP2C19 activity, but not CYP3A, CYP1A2, and CYP2C9 activities. The findings indicate that T2DM has a significant downregulating impact on CYP2C19 activity, but not on CYP3A, CYP1A2, and CYP2C9 activities and protein concentrations in patients with obesity. Hence, the effect of T2DM seems to be isoform-specific.

• Kvitne, Kine Eide; Hole, Kristine; Krogstad, Veronica; Wollmann, Birgit Malene Tovik; Wegler, Christine & Johnson, Line Kristin [Show all 19 contributors for this article] (2022). Correlations between 4β-hydroxycholesterol and hepatic and intestinal CYP3A4: protein expression, microsomal ex vivo activity, and in vivo activity in patients with a wide body weight range. European Journal of Clinical Pharmacology. ISSN 0031-6970. 78(8), p. 1289–1299. doi: 10.1007/s00228-022-03336-9. Full text in Research Archive Show summary

  Purpose Variability in cytochrome P450 3A4 (CYP3A4) metabolism is mainly caused by non-genetic factors, hence providing a need for accurate phenotype biomarkers. Although 4β-hydroxycholesterol (4βOHC) is a promising endogenous CYP3A4 biomarker, additional investigations are required to evaluate its ability to predict CYP3A4 activity. This study investigated the correlations between 4βOHC concentrations and hepatic and intestinal CYP3A4 protein expression and ex vivo microsomal activity in paired liver and jejunum samples, as well as in vivo CYP3A4 phenotyping (midazolam) in patients with a wide body weight range. Methods The patients (n = 96; 78 with obesity and 18 normal or overweight individuals) were included from the COCKTAIL-study (NCT02386917). Plasma samples for analysis of 4βOHC and midazolam concentrations, and liver (n = 56) and jejunal (n = 38) biopsies were obtained. The biopsies for determination of CYP3A4 protein concentration and microsomal activity were obtained during gastric bypass or cholecystectomy. In vivo CYP3A4 phenotyping was performed using semi-simultaneous oral (1.5 mg) and intravenous (1.0 mg) midazolam. Results 4βOHC concentrations were positively correlated with hepatic microsomal CYP3A4 activity (ρ = 0.53, p < 0.001), and hepatic CYP3A4 concentrations (ρ = 0.30, p = 0.027), but not with intestinal CYP3A4 concentrations (ρ = 0.18, p = 0.28) or intestinal microsomal CYP3A4 activity (ρ = 0.15, p = 0.53). 4βOHC concentrations correlated weakly with midazolam absolute bioavailability (ρ =  − 0.23, p = 0.027) and apparent oral clearance (ρ = 0.28, p = 0.008), but not with systemic clearance (ρ =  − 0.03, p = 0.81). Conclusion These findings suggest that 4βOHC concentrations reflect hepatic, but not intestinal, CYP3A4 activity. Further studies should investigate the potential value of 4βOHC as an endogenous biomarker for individual dose requirements of intravenously administered CYP3A4 substrate drugs.

• Kvitne, Kine Eide; Krogstad, Veronica; Wegler, Christine; Johnson, Line Kristin; Kringen, Marianne K. & Hovd, Markus Herberg [Show all 19 contributors for this article] (2022). Short- and long-term effects of body weight, calorie restriction and gastric bypass on CYP1A2, CYP2C19 and CYP2C9 activity. British Journal of Clinical Pharmacology. ISSN 0306-5251. 88(9), p. 4121–4133. doi: 10.1111/bcp.15349. Full text in Research Archive Show summary

  Roux-en-Y gastric bypass (RYGB) may influence drug disposition due to surgery-induced gastrointestinal alterations and/or subsequent weight loss. The objective was to compare short- and long-term effects of RYGB and diet on the metabolic ratios of paraxanthine/caffeine (cytochrome P450 [CYP] 1A2 activity), 5-hydroxyomeprazole/omeprazole (CYP2C19 activity) and losartan/losartan carboxylic acid (CYP2C9 activity), and cross-sectionally compare these CYP-activities with normal-to-overweight controls. Methods This trial included patients with severe obesity preparing for RYGB (n = 40) or diet-induced (n = 41) weight loss, and controls (n = 18). Both weight loss groups underwent a 3-week low-energy diet (<1200 kcal/day, weeks 0-3) followed by a 6-week very-low-energy diet or RYGB (both <800 kcal/day, weeks 3-9). Follow-up time was 2 years, with four pharmacokinetic investigations. Results Mean ± SD weight loss from baseline was similar in the RYGB-group (13 ± 2.4%) and the diet group (10.5 ± 3.9%) at week 9, but differed at year 2 (RYGB −30 ± 6.9%, diet −3.1 ± 6.3%). From weeks 0 to 3, mean (95% confidence interval [CI]) CYP2C19 activity similarly increased in both groups (RYGB 43% [16, 55], diet 48% [22, 60]). Mean CYP2C19 activity increased by 30% (2.6, 43) after RYGB (weeks 3-9), but not in the diet-group (between-group difference −0.30 [−0.63, 0.03]). CYP2C19 activity remained elevated in the RYGB group at year 2. Baseline CYP2C19 activity was 2.7-fold higher in controls compared with patients with obesity, whereas no difference was observed in CYP1A2 and CYP2C9 activities. Conclusion Our findings suggest that CYP2C19 activity is lower in patients with obesity and increases following weight loss. This may be clinically relevant for drug dosing. No clinically significant effect on CYP1A2 and CYP2C9 activities was observed.

• Wegler, Christine; Wisniewski, Jacek R.; Robertsen, Ida; Christensen, Hege; Hertel, Jens Kristoffer & Hjelmesæth, Jøran Sture [Show all 10 contributors for this article] (2022). Drug disposition protein quantification in matched human jejunum and liver from donors with obesity. Clinical Pharmacology and Therapeutics. ISSN 0009-9236. 111(5), p. 1142–1154. doi: 10.1002/cpt.2558. Full text in Research Archive Show summary

  Mathematical models, such as physiologically based pharmacokinetic (PBPK) models, are used to predict e.g., drug disposition and toxicity. However, populations differ in the abundance of proteins involved in these processes. To improve the building and refinement of such models, they must take into account these inter-individual variabilities. In this study, we used global proteomics to characterize the protein composition of jejunum and liver from 37 donors with obesity enrolled in the COCKTAIL study. Liver protein levels from the 37 donors were further compared with those from donors without obesity. We quantified thousands of proteins and could present the expression of several drug-metabolizing enzymes, for the first time, in jejunum, many of which belong to the cytochrome P450 (e.g., CYP2U1) and the amine oxidase [flavin-containing] (e.g., MAOA) families. Although we show that many metabolizing enzymes had greater expression in liver, others had higher expression in jejunum (such as, MAOA and CES2), indicating the role of the small intestine in extrahepatic drug metabolism. We further show that proteins involved in drug disposition are not correlated in the two donor-matched tissues. These proteins also do not correlate with physiological factors such as BMI, age, and inflammation status in either tissue. Furthermore, the majority of these proteins are not differently expressed in donors with or without obesity. Nonetheless, inter-individual differences were considerable, with implications for personalized prediction models and systems pharmacology.

• Kvitne, Kine Eide; Robertsen, Ida; Skovlund, Eva; Christensen, Hege Staaland; Krogstad, Veronica & Wegler, Christine [Show all 18 contributors for this article] (2021). Short- and long-term effects of body weight loss following calorie restriction and gastric bypass on CYP3A-activity – a non-randomized three-armed controlled trial. Clinical and Translational Science (CTS). ISSN 1752-8054. doi: 10.1111/cts.13142. Full text in Research Archive
• Gustavsen, Marte Theie; Midtvedt, Karsten; Robertsen, Ida; Woillard, Jean-Baptiste; Debord, Jean & Klaasen, Rolf [Show all 9 contributors for this article] (2020). Fasting Status and Circadian Variation Must be Considered When Performing AUC-based Therapeutic Drug Monitoring of Tacrolimus in Renal Transplant Recipients. Clinical and Translational Science (CTS). ISSN 1752-8054. 13(6), p. 1327–1335. doi: 10.1111/cts.12833.
• Krogstad, Veronica; Peric, Alexandra; Robertsen, Ida; Kringen, Marianne K.; Vistnes, Maria & Hjelmesæth, Jøran [Show all 15 contributors for this article] (2020). Correlation of body weight and composition with hepatic activities of cytochrome P450 enzymes . Journal of Pharmaceutical Sciences. ISSN 0022-3549. 110(1), p. 432–437. doi: 10.1016/j.xphs.2020.10.027. Full text in Research Archive
• Lemaitre, Florian; Vethe, Nils Tore; DʼAvolio, Antonio; Tron, Camille; Robertsen, Ida & De Winter, Brenda [Show all 14 contributors for this article] (2020). Measuring intracellular concentrations of calcineurin inhibitors: Expert consensus from the international association of therapeutic drug monitoring and clinical toxicology expert panel. Therapeutic Drug Monitoring. ISSN 0163-4356. 42(5), p. 665–670. doi: 10.1097/FTD.0000000000000780.
• Wegler, Christine; Garcia, Luna Prieto; Klinting, Signe; Robertsen, Ida; Wisniewski, Jacek R. & Hjelmesæth, Jøran [Show all 10 contributors for this article] (2020). Proteomics‐informed prediction of rosuvastatin plasma profiles in patients with a wide range of body weight. Clinical Pharmacology and Therapeutics. ISSN 0009-9236. 109(3), p. 762–771. doi: 10.1002/cpt.2056. Full text in Research Archive
• Egeland, Erlend Johannessen; Witczak, Bartlomiej J; Zare, Hasse Khiabani; Christensen, Hege Staaland; Åsberg, Anders & Robertsen, Ida (2020). Chronic Inhibition of CYP3A is Temporarily Reduced by Each Hemodialysis Session in Patients With End‐Stage Renal Disease. Clinical Pharmacology and Therapeutics. ISSN 0009-9236. 108(4), p. 866–873. doi: 10.1002/cpt.1875.
• Gustavsen, Marte Theie; Midtvedt, Karsten; Vethe, Nils Tore; Robertsen, Ida; Bergan, Stein & Åsberg, Anders (2020). Tacrolimus area under the concentration versus time curve monitoring, using home-based volumetric absorptive capillary microsampling. Therapeutic Drug Monitoring. ISSN 0163-4356. 42(3), p. 407–414. doi: 10.1097/FTD.0000000000000697.
• Åsberg, Anders; Bjerre, Anna Kristina; Almaas, Runar; Luis-Lima, Sergio; Robertsen, Ida & Salvador, Cathrin Lytomt [Show all 10 contributors for this article] (2019). Measured GFR by Utilizing Population Pharmacokinetic Methods to Determine Iohexol Clearance. Kidney International Reports. ISSN 2468-0249. 5(2), p. 189–198. doi: 10.1016/j.ekir.2019.11.012. Full text in Research Archive
• Krogstad, Veronica; Peric, Alexandra; Robertsen, Ida; Kringen, Marianne K.; Wegler, Christine & Angeles, Philip Carlo Soriano [Show all 13 contributors for this article] (2019). A Comparative Analysis of Cytochrome P450 Activities in Paired Liver and Small Intestinal Samples from Patients with Obesity. Drug Metabolism And Disposition. ISSN 0090-9556. 48(1), p. 8–17. doi: 10.1124/DMD.119.087940.
• Angeles, Philip Carlo Soriano; Robertsen, Ida; Seeberg, Lars Thomas; Krogstad, Veronica; Skattebu, Julie & Sandbu, Rune [Show all 8 contributors for this article] (2019). The influence of bariatric surgery on oral drug bioavailability in patients with obesity: A systematic review. Obesity Reviews. ISSN 1467-7881. 20(9), p. 1299–1311. doi: 10.1111/obr.12869. Full text in Research Archive Show summary

  Anatomical changes in the gastrointestinal tract and subsequent weight loss may influence drug disposition and thus drug dosing following bariatric surgery. This review systematically examines the effects of bariatric surgery on drug pharmacokinetics, focusing especially on the mechanisms involved in restricting oral bioavailability. Studies with a longitudinal before‐after design investigating the pharmacokinetics of at least one drug were reviewed. The need for dose adjustment following bariatric surgery was examined, as well as the potential for extrapolation to other drugs subjected to coinciding pharmacokinetic mechanisms. A total of 22 original articles and 32 different drugs were assessed. The majority of available data is based on Roux‐en‐Y gastric bypass (RYGBP) (18 of 22 studies), and hence, the overall interpretation is more or less limited to RYGBP. In the case of the majority of studied drugs, an increased absorption rate was observed early after RYGBP. The effect on systemic exposure allows for a low degree of extrapolation, including between drugs subjected to the same major metabolic and transporter pathways. On the basis of current understanding, predicting the pharmacokinetic change for a specific drug following RYGBP is challenging. Close monitoring of each individual drug is therefore recommended in the early postsurgical phase. Future studies should focus on the long‐term effects of bariatric surgery on drug disposition, and they should also aim to disentangle the effects of the surgery itself and the subsequent weight loss.

• Strøm Halden, Thea Anine; Kvitne, Kine Eide; Midtvedt, Karsten; Rajakumar, Laavanyaah; Robertsen, Ida & Brox, Jan [Show all 10 contributors for this article] (2019). Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus. Diabetes Care. ISSN 0149-5992. 42(6), p. 1067–1074. doi: 10.2337/dc19-0093. Full text in Research Archive
• Krogstad, Veronica; Vethe, Nils Tore; Robertsen, Ida; Hasvold, Grete; Ose, Anne-Marthe Due & Hermann, Monica [Show all 12 contributors for this article] (2018). Determination of Tacrolimus Concentration and Protein Expression of P-Glycoprotein in Single Human Renal Core Biopsies. Therapeutic Drug Monitoring. ISSN 0163-4356. 40(3), p. 292–300. doi: 10.1097/FTD.0000000000000510.
• Egeland, Erlend Johannessen; Reisæter, Anna Varberg; Robertsen, Ida; Midtvedt, Karsten; Strøm, Erik Heyerdahl & Holdaas, Hallvard [Show all 8 contributors for this article] (2018). High tacrolimus clearance ? a risk factor for development of interstitial fibrosis and tubular atrophy in the transplanted kidney: a retrospective single-center cohort study. Transplant International. ISSN 0934-0874. 32(3), p. 257–269. doi: 10.1111/tri.13356.
• Robertsen, Ida; Debord, Jean; Åsberg, Anders; Marquet, Pierre & Woillard, Jean-Baptiste (2018). A Limited Sampling Strategy to Estimate Exposure of Everolimus in Whole Blood and Peripheral Blood Mononuclear Cells in Renal Transplant Recipients Using Population Pharmacokinetic Modeling and Bayesian Estimators. Clinical Pharmacokinetics. ISSN 0312-5963. 57(11), p. 1459–1469. doi: 10.1007/s40262-018-0646-5.
• Hjelmesæth, Jøran; Åsberg, Anders; Andersson, Shalini; Sandbu, Rune; Robertsen, Ida & Johnson, Line Kristin [Show all 16 contributors for this article] (2018). Impact of body weight, low energy diet and gastric bypass on drug bioavailability, cardiovascular risk factors and metabolic biomarkers: protocol for an open, non-randomised, three-armed single centre study (COCKTAIL). BMJ Open. ISSN 2044-6055. 8:e021878(5), p. 1–10. doi: 10.1136/bmjopen-2018-021878. Full text in Research Archive
• Egeland, Erlend Johannessen; Robertsen, Ida; Hermann, Monica; Midtvedt, Karsten; Størset, Elisabet & Gustavsen, Marte Theie [Show all 12 contributors for this article] (2017). High tacrolimus clearance is a risk factor for acute rejection in the early phase after renal transplantation. Transplantation. ISSN 0041-1337. 101(8), p. e273–e279. doi: 10.1097/TP.0000000000001796. Full text in Research Archive
• Hermann, Monica; Robertsen, Ida & Christensen, Hege Staaland (2015). Immunologisk aktivitet og biologiske legemidler påvirker legemiddelmetabolisme og -transport. Norsk Farmaceutisk Tidsskrift. ISSN 0029-1935. 123(6), p. 22–25.
• Robertsen, Ida; Vethe, Nils Tore; Midtvedt, Karsten; Falck, Pål; Christensen, Hege Staaland & Åsberg, Anders (2015). Closer to the site of action: everolimus concentrations in peripheral blood mononuclear cells correlate well with whole blood concentrations. Therapeutic Drug Monitoring. ISSN 0163-4356. 37(5), p. 675–680. doi: 10.1097/FTD.0000000000000185.
• Robertsen, Ida; Åsberg, Anders; Ingerø Olsen, Aleksander; Vethe, Nils Tore; Bremer, Sara & Bergan, Stein [Show all 7 contributors for this article] (2015). Use of generic tacrolimus in elderly renal transplant recipients: Precaution is needed. Transplantation. ISSN 0041-1337. 99(3), p. 528–532. doi: 10.1097/TP.0000000000000384.
• Robertsen, Ida; Åsberg, Anders; Granseth, Tone; Vethe, Nils Tore; Akhlaghi, Fatemeh & Ghareeb, Mwlod [Show all 10 contributors for this article] (2014). More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients. Transplantation. ISSN 0041-1337. 97(12), p. 1266–1272. doi: 10.1097/01.TP.0000443225.66960.7e.
• Robertsen, Ida; Falck, Pål; Andreassen, Arne K.; Næss, Nina Kaajal; Lunder, Niclas & Christensen, Hege Staaland [Show all 8 contributors for this article] (2013). Endomyocardial, intralymphocyte and whole blood concentrations of ciclosporin A in heart transplant recipients. Transplantation Research. ISSN 2047-1440. 2(5). doi: 10.1186/2047-1440-2-5.
• Amundsen, Rune; Åsberg, Anders; Robertsen, Ida; Vethe, Nils Tore; Bergan, Stein & Hartmann, Anders [Show all 7 contributors for this article] (2009). Rimonabant Affects Cyclosporine A, but Not Tacrolimus Pharmacokinetics in Renal Transplant Recipients. Transplantation. ISSN 0041-1337. 87(8), p. 1221–1224.

View all works in Cristin

• Thoresen, G. Hege; Simonsen, terje; Christensen, Hege; Johansen, Harald Thidemann; Kase, Eili Tranheim & Robertsen, Ida [Show all 9 contributors for this article] (2021). Basal farmakologi. Fagbokforlaget. ISBN 9788245033557. 405 p.
• Thoresen, G. Hege; Solberg, Rigmor; Johansen, Harald Thidemann; Kase, Eili Tranheim; Rustan, Arild Christian & Christensen, Hege [Show all 7 contributors for this article] (2020). Illustrert farmakologi. Fagbokforlaget. ISBN 9788245033564. 392 p.

View all works in Cristin

• Kvitne, Kine Eide; Hole, Kristine; Molden, Espen & Robertsen, Ida (2022). Response to: “Utility of endogenous 4β-hydroxycholesterol as a biomarker to assess cytochrome P 450 3A (CYP3A) activity: not quite ready for prime time”. European Journal of Clinical Pharmacology. ISSN 0031-6970. doi: 10.1007/s00228-022-03387-y.
• Robertsen, Ida; Åsberg, Anders; Jenssen, Trond Geir; Gence, Berfin; Vethe, Nils Tore & Midtvedt, Karsten [Show all 8 contributors for this article] (2021). Increased systemic exposure of once-daily tacrolimus in renal transplant recipients on marine omega-3 fatty acid supplementation. Transplant International. ISSN 0934-0874. doi: 10.1111/tri.13917.
• Åsberg, Anders; Bergan, Stein; Bjørkto, Magnus; Mjøen, Geir; Reisæter, Anna Varberg & Robertsen, Ida [Show all 7 contributors for this article] (2020). Severe mycophenolate intoxication in a solid organ transplant recipient - No intervention actually needed. Transplantation direct. ISSN 2373-8731. 6:e609, p. 1–4. doi: 10.1097/TXD.0000000000001058.
• Johnson, Line Kristin; Sandbu, Rune; Robertsen, Ida; Åsberg, Anders; Andersson, Tommy & Andersson, Shalini [Show all 8 contributors for this article] (2019). Effect of gastric bypass and very-low energy diet on cardiometabolic risk factors. Surgery for Obesity and Related Diseases. ISSN 1550-7289. 15, p. S114–S114. doi: 10.1016/j.soard.2019.08.232.
• Angeles, Philip Carlo Soriano; Robertsen, Ida; Seeberg, Lars Thomas; Krogstad, Veronica; Sandbu, Rune & Åsberg, Anders [Show all 7 contributors for this article] (2019). Reply to letter: “What about drug bioavailability in patients who had bariatric surgery and dependent on immunosuppressives?”. Obesity Reviews. ISSN 1467-7881. 21(2). doi: 10.1111/obr.12954.
• Robertsen, Ida; Woillard, Jean-Baptiste & Åsberg, Anders (2019). Why dose adjust systemic exposure when looking for associations with adverse events in tacrolimus‐treated transplant recipients? British Journal of Clinical Pharmacology. ISSN 0306-5251. 86(12), p. 2535–2535. doi: 10.1111/bcp.13984.
• Egeland, Erlend Johannessen; Størset, Elisabet; Robertsen, Ida; Hermann, Monica; Midtvedt, Karsten & Gustavsen, Marte Theie [Show all 10 contributors for this article] (2018). The Authors' Reply. Transplantation. ISSN 0041-1337. 102(1), p. e43–e44. doi: 10.1097/TP.0000000000001961.
• Egeland, Erlend Johannessen; Robertsen, Ida; Hermann, Monica; Midtvedt, Karsten; Størset, Elisabet & Gustavsen, Marte Theie [Show all 12 contributors for this article] (2017). High tacrolimus clearance may predict rejection and chronic damage to the transplanted kidney.
• Egeland, Erlend Johannessen; Robertsen, Ida; Hermann, Monica; Midtvedt, Karsten; Størset, Elisabet & Gustavsen, Marte Theie [Show all 12 contributors for this article] (2017). High tacrolimus clearance – a risk factor for acute rejection and fibrosis in the transplanted kidney.
• Egeland, Erlend Johannessen; Robertsen, Ida; Hermann, Monica; Midtvedt, Karsten; Størset, Elisabet & Gustavsen, Marte Theie [Show all 12 contributors for this article] (2017). High tacrolimus clearance and acute rejection risk after renal transplantation.
• Åsberg, Anders; Robertsen, Ida & Midtvedt, Karsten (2017). How to report and interpret bioequivalence data in solid organ transplant recipients. Transplantation. ISSN 0041-1337. 101(11), p. e347–e347. doi: 10.1097/TP.0000000000001894.
• Ose, Anne M; Krogstad, Veronica; Hasvold, Grete; Robertsen, Ida; Egeland, Erlend Johannessen & Hermann, Monica [Show all 9 contributors for this article] (2017). Optimalisering av metode for kvantifisering av CYP3A5 og P_glykoprotein i små nyrebiopsier.
• Vu, Martin; Krogstad, Veronica; Johnson, Line Kristin; Angeles, Philip Carlo S; Hasvold, Grete & Hermann, Monica [Show all 13 contributors for this article] (2017). Effect of low calorie diet on the absolute bioavailability of midazolam in patients with severe obesity.
• Egeland, Erlend Johannessen; Hermann, Monica; Robertsen, Ida; Midtvedt, Karsten; Hartmann, Anders & Reisæter, Anna Varberg [Show all 12 contributors for this article] (2016). High tacrolimus clearance is a risk factor for acute rejection early after renal transplantation.
• Le, Peter Huy Vo; Robertsen, Ida; Åsberg, Anders; Christensen, Hege Staaland & Hermann, Monica (2016). Utvikling av en sensitiv LC-MS/MS-metode for å kvantifisere midazolam og metabolitter i pasienter med sykelig overvekt før og etter gastrisk bypass-operasjon.
• Ulvmoen, Anders; Robertsen, Ida; Åsberg, Anders; Christensen, Hege Staaland & Hermann, Monica (2015). Utvikling av en sensitiv LC-MS/MS-metode for å kvantifisere midazolam og metabolitter in vitro og i sykelig overvektige pasienter.
• Ahlsen, Kathrine; Robertsen, Ida; Midtvedt, Karsten; Åsberg, Anders & Christensen, Hege Staaland (2014). Aktivitet av P-glykoprotein i mononukleære celler fra perifert blod.
• Robertsen, Ida; Åsberg, Anders; Granseth, Tone; Vethe, Nils Tore; Akhlaghi, Fatemeh & Ghareeb, Mwlod [Show all 10 contributors for this article] (2013). ROSUVASTATIN IS A POTENT LIPID-LOWERING STATIN IN RENAL TRANSPLANT RECIPIENTS RECEIVING EVEROLIMUS. Transplant International. ISSN 0934-0874. 26, p. 50–50.
• Robertsen, Ida; Falck, Pål; Næss, Nina Kaajal; Andreassen, Arne K.; Gullestad, Lars & Christensen, Hege Staaland [Show all 7 contributors for this article] (2012). Endomyovardial, intralymphocyte and whole blood concentrations of cyclosporine A in heart transplant recipients.
• Jensstuen, Ågot K; Robertsen, Ida; Amundsen, Rune & Christensen, Hege Staaland (2011). CYP3A4-mediert metabolisme av cyklosporin i insektsmikrosomer.
• Amundsen, Rune; Åsberg, Anders; Robertsen, Ida; Vethe, Nils Tore; Bergan, Stein & Midtvedt, Karsten (2009). Rimonabant Affects Cyclosporine A, but Not Tacrolimus Pharmacokinetics in Renal Transplant Recipients.

View all works in Cristin